A nanomedicine based on stoichiometric coordination of camptothecin and organoplatinum (II) for synergistic antitumor therapy
Source abstract
Abstract
Precise combination therapy, involving multiple chemotherapeutics with pharmacologically synergistic antitumor effects, is a promising approach to address the challenge of monotherapy with insufficient activity towards their targets of interest. We employed Pt←pyridine coordination-driven assembly to construct a stoichiometric coordination complex of camptothecin and organoplatinum (II) (Pt-CPT). The Pt-CPT complex exhibited a remarkable synergistic effect toward several tumor cell lines, which is equal to the optimal synergistic effect of (PEt3)2Pt(OTf)2 (Pt) and CPT mixture at various ratios. An amphiphilic polymer with H2O2-responsiveness and glutathione (GSH)-depleting ability (PO) was used to encapsulate Pt-CPT complex to enable the nanomedicine (Pt-CPT@PO) with prolonged blood circulation and elevated tumor accumulation. The Pt-CPT@PO nanomedicine exhibited remarkable synergistic antitumor efficacy and antimetastatic effect on a mice orthotopic breast tumor model. This work demonstrated the potential of stoichiometric coordination-driven assembly of organic therapeutics with metal-based drugs in developing advanced nanomedicine with optimal synergistic antitumor activity. STATEMENT OF SIGNIFICANCE: In this study, for the first time, we employed Pt←pyridine coordination-driven assembly to construct a stoichiometric coordination complex of camptothecin and organoplatinum (II) (Pt-CPT), with an optimal synergistic effect at various ratios. Then it was encapsulated into an amphiphilic polymer with H2O2-responsiveness and glutathione (GSH)-depleting ability (PO) to enable the nanomedicine (Pt-CPT@PO) with prolonged blood circulation and elevated tumor accumulation. The Pt-CPT@PO nanomedicine exhibited remarkable synergistic antitumor efficacy and antimetastatic effect on a mice orthotopic breast tumor model.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Metal complexes synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Topoisomerase I inhibitors: camptothecins and beyond10.1038/nrc1977 ↗
2. Repair of topoisomerase I-mediated DNA damage10.1016/S0079-6603(06)81005-6 ↗
3. Topoisomerase I-mediated DNA damage10.1016/S0065-230X(01)80016-6 ↗
4. Repair of and checkpoint response to topoisomerase I-mediated DNA damage10.1016/j.mrfmmm.2003.08.016 ↗
5. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation10.1038/cr.2017.54 ↗
6. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy10.1073/pnas.1011368107 ↗
7. Beta-cyclodextrin modified Pt(II) metallacycle-based supramolecular hyperbranched polymer assemblies for DOX delivery to liver cancer cells10.1073/pnas.2007798117 ↗
8. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers10.1073/pnas.0711714105 ↗
9. Cisplatin: the first metal based anticancer drug10.1016/j.bioorg.2019.102925 ↗
10. Platinum-based drugs: past, present and future10.1007/s00280-016-2976-z ↗
11. Photo-reduction with NIR light of nucleus-targeting PtIV nanoparticles for combined tumor-targeted chemotherapy and photodynamic immunotherapy10.1002/anie.202201486 ↗
12. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
13. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs10.1021/acs.chemrev.5b00597 ↗
14. The rediscovery of platinum-based cancer therapy10.1038/s41568-020-00308-y ↗
15. A near-infrared-II polymer with tandem fluorophores demonstrates superior biodegradability for simultaneous drug tracking and treatment efficacy feedback10.1021/acsnano.1c00076 ↗
16. Platinum-based drugs for cancer therapy and anti-tumor strategies10.7150/thno.69424 ↗
17. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance10.1038/s41551-021-00728-7 ↗
18. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer10.1056/NEJMoa003034 ↗
19. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma10.1200/JCO.2008.17.1249 ↗
20. Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery10.1021/ja409686x ↗
21. Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals10.1021/ja5105848 ↗
22. Tumor-activatable nanoparticles target low-density lipoprotein receptor to enhance drug delivery and antitumor efficacy10.1002/advs.202201614 ↗
23. A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis10.1016/j.biomaterials.2022.121781 ↗
24. Recapitulating spatiotemporal tumor heterogeneity in vitro through engineered breast cancer microtissues10.1016/j.actbio.2018.04.028 ↗
25. Trackable supramolecular fusion: cage to cage transformation of tetraphenylethylene-based metalloassemblies10.1002/anie.202000078 ↗
26. Self-assembly of porphyrin-containing metalla-assemblies and cancer photodynamic therapy10.1021/acs.inorgchem.9b02775 ↗
27. In situ assembly of platinum(II)-metallopeptide nanostructures disrupts energy homeostasis and cellular metabolism10.1021/jacs.2c03215 ↗
28. Antitumor activity of a unique polymer that incorporates a fluorescent self-assembled metallacycle10.1021/jacs.7b09224 ↗
29. Designed conformation and fluorescence properties of self-assembled phenazine-cored platinum(II) metallacycles10.1021/jacs.9b01368 ↗
30. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile10.1073/pnas.1207670109 ↗
31. understanding the effects of coordination and self-assembly on an emissive phenothiazine10.1021/jacs.9b00363 ↗
32. Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy10.1186/s12951-022-01531-5 ↗
33. A self-assembled Ru-Pt metallacage as a lysosome-targeting photosensitizer for 2-photon photodynamic therapy10.1073/pnas.1912549116 ↗
34. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance10.1021/acs.nanolett.8b01924 ↗
35. Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging10.1021/acsnano.0c05541 ↗
36. Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models10.1021/acsnano.0c06190 ↗
37. Rationally designed polymer conjugate for tumor-specific amplification of oxidative stress and boosting antitumor immunity10.1021/acs.nanolett.9b05265 ↗
38. Self-assembly of cationic, tetranuclear, Pt(II) and Pd(II) macrocyclic squares. X-ray crystal structure of [Pt2+(dppp)(4,4′-bipyridyl)2-OSO2CF3]410.1021/ja00128a015 ↗
39. A discrete organoplatinum(II) metallacage as a multimodality theranostic platform for cancer photochemotherapy10.1038/s41467-018-06574-7 ↗
40. An NIR discrete metallacycle constructed from perylene bisimide and tetraphenylethylene fluorophores for imaging-guided cancer radio-chemotherapy10.1002/adma.202106388 ↗
41. Host-guest complexation-mediated codelivery of anticancer drug and photosensitizer for cancer photochemotherapy10.1073/pnas.1902029116 ↗
42. Dual-emissive platinum(II) metallacage with a sensitive oxygen response for imaging of hypoxia and imaging-guided chemotherapy10.1002/anie.202009442 ↗
43. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine?10.1021/ja036960d ↗
44. A systematic strategy of combinational blow for overcoming cascade drug resistance via NIR-light-triggered hyperthermia10.1002/adma.202100599 ↗
45. Polymeric nanoparticles integrated from discrete organoplatinum(II) metallacycle by stepwise post-assembly polymerization for synergistic cancer therapy10.1021/acs.chemmater.0c00615 ↗
46. Design strategies and applications of ROS-responsive phenylborate ester-based nanomedicine10.1021/acsbiomaterials.0c01190 ↗
47. Biodegradable charge-transfer complexes for glutathione depletion induced ferroptosis and NIR-II photoacoustic imaging guided cancer photothermal therapy10.1002/anie.202014852 ↗
48. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer10.7150/thno.29820 ↗
49. Reactive oxygen species (ROS)-responsive prodrugs, probes, and theranostic prodrugs: applications in the ROS-related diseases10.1021/acs.jmedchem.0c01704 ↗
50. GSSG/GSH ratios in cryopreserved rat and human hepatocytes as a biomarker for drug induced oxidative stress10.1016/j.tiv.2014.04.017 ↗
51. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
52. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?10.1021/acs.bioconjchem.6b00437 ↗
53. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
54. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
55. Targeting metastasis10.1038/nrc.2016.25 ↗
56. Molecular pathogenesis of bone metastases in breast cancer: proven and emerging therapeutic targets10.5306/wjco.v5.i3.335 ↗
57. Breast cancer bone metastases: pathogenesis and therapeutic targets10.1016/j.biocel.2018.01.003 ↗